# Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis

> **NCT06444165** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 55 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Lebrikizumab Pen

## Key facts

- **NCT ID:** NCT06444165
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-04
- **Primary completion:** 2024-06-10
- **Final completion:** 2024-06-10
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06444165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06444165, "Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06444165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*